P170 Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H
Ritchlin C, Kavanaugh A, Kristensen L, Merola J, Strober B, Lisse J, Bolce R, Sapin C, Pustizzi J, McGonagle D. P170 Ixekizumab significantly improved quality of life and joint pain in patients with psoriatic arthritis, nail disease and distal interphalangeal joint involvement from SPIRIT-H2H. Rheumatology 2024, 63: keae163.209. DOI: 10.1093/rheumatology/keae163.209.Peer-Reviewed Original ResearchHealth Assessment Questionnaire-Disability IndexDermatology Life Quality IndexSF-36Quality of lifeJoint painMental and Physical Component Summary scoresQoL measuresConsulting feesUCB PharmaPhysical component summary scoreHealth care providersComponent summary scoresSF-36 MCSSF-36 PCSIXE-treated patientsClinically important improvementNail Psoriasis Severity IndexADA-treated patientsDistal interphalangeal jointDistal interphalangeal joint involvementDermatology Life Quality Index scoresStatistically significant improvementVisual analogue scaleCare providersJoint involvement